Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough childhood cancer: experimental drug targets aurora kinase

NCT ID NCT04106219

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This early-stage trial tests an experimental drug called LY3295668 erbumine in children whose neuroblastoma has returned or not responded to treatment. The study aims to find a safe dose and see if the drug can shrink tumors, either alone or with standard chemotherapy. About 71 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3295668 erbumine (aurora kinase A inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if the drug works. Side effects may be significant, and the drug may not shrink tumors in most participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 71 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue. * Participants must be able to swallow capsules. Exclusion Criteria: * Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant. * Participants must not have untreated tumor that has spread to the brain or spinal cord. * Participants must not have a serious active disease other than neuroblastoma. * Participants must not have a condition affecting absorption. * Participants must not have had prior aurora kinase inhibitor exposure. * Participants must not have a known allergy to the study treatment. * Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroblastoma

Contacts and locations

Locations

  • Alder Hey Children's Hospital

    Liverpool, L14 5AB, United Kingdom

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, 69373 CEDEX 08, France

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cincinnati Childrens Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • Hospital Infantil Universitario Niño Jesús

    Madrid, 28009, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], 8035, Spain

  • Institut Curie

    Paris, 75248, France

  • Istituto Nazionale dei Tumori

    Milan, Lombardy, 20133, Italy

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, 104-0045, Japan

  • Perth Children's Hospital

    Perth, Western Australia, 6009, Australia

  • Texas Childrens Hospital

    Houston, Texas, 77030, United States

  • UCSF Medical Center at Mission Bay

    San Francisco, California, 94158, United States

  • UZ Gent

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • University of Chicago - Comer Children's Hospital

    Chicago, Illinois, 60637, United States

  • Universitätsklinikum Köln

    Cologne, 50924, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.